ライフサイエンスコーパス: nonresponder

1 %) occurred (i.e., changes from responder to nonresponder).

2 (present in 55% of responders and in 36% of nonresponders).

3 progression (these patients were counted as nonresponders).

4 ew York Heart Association class or worsened (nonresponders).

5 s responder and 19 follow-up examinations as nonresponder.

6 rugs and differentiate between responder and nonresponder.

7 other changes classified the patient as CRT nonresponder.

8 g cells, were similar between responders and nonresponders.

9 condensed chromatin structure compared with nonresponders.

10 ents with persistent disease were classed as nonresponders.

11 ugh a significant number of patients will be nonresponders.

12 gnificantly different between responders and nonresponders.

13 lesion glycolysis (P = 0.04) after IC1 than nonresponders.

14 y to help predict survival of responders and nonresponders.

15 ed as responders and 15 individuals (60%) as nonresponders.

16 and 6 in the placebo group) were considered nonresponders.

17 acteristics indicated more severe disease in nonresponders.

18 ctive and placebo, as well as responders and nonresponders.

19 hieved SU to egg; all others were considered nonresponders.

20 ial TACE and enabled clear identification of nonresponders.

21 ever, 7 of 25 patients (28%) were considered nonresponders.

22 a-glucuronidase gene abundance compared with nonresponders.

23 pression at diagnosis between responders and nonresponders.

24 r NKG2A on CD56(dim) NK cells, compared with nonresponders.

25 ) mRNA expression compared with methotrexate nonresponders.

26 pressure and reliably detects responders and nonresponders.

27 pplementation in HIV-infected, older vaccine nonresponders.

28 nders have a better PFS and OS compared with nonresponders.

29 med routinely to distinguish responders from nonresponders.

30 monitoring between treatment responders and nonresponders.

31 id not distinguish treatment responders from nonresponders.

32 and skin prick test titration compared with nonresponders.

33 was observed between treated responders and nonresponders.

34 with anxiety are at risk for being treatment nonresponders.

35 could differentiate eventual responders from nonresponders.

36 ontacts did not discriminate responders from nonresponders.

37 -)CD27(-)CD28(-)) compared with CMV-infected nonresponders.

38 reg expansion between HD IL-2 responders and nonresponders.

39 inally differentiated T cells, compared with nonresponders.

40 atients were responders, and 9 patients were nonresponders.

41 e implantation but may be considered for CRT nonresponders.

42 was unique in showing increased levels among nonresponders.

43 dence interval : 3.9, 8.4), respectively, in nonresponders.

44 (15%) were not assessable and assumed to be nonresponders.

45 e lower in responders compared with those in nonresponders.

46 ndex was also investigated in responders and nonresponders.

47 and +3.1% (-1.6% to 7.4%) in fluid challenge nonresponders.

48 X treatment is not modified in responders or nonresponders.

49 ients missing week-13 values were considered nonresponders.

50 7 responders, whereas it remained high in 4 nonresponders.

51 In these latter, 39/104 (37.5%) were nonresponders.

52 ied as responders and 128 were classified as nonresponders.

53 tion of IL-15Ralpha expression compared with nonresponders.

54 2.7 months; P = .01; HR, 3.1) compared with nonresponders.

55 ; P < .001) of the QLQ-C15-PAL compared with nonresponders.

56 patient gut microbiome of responders versus nonresponders.

57 23% +/- 9% in responders and by 8% +/- 3% in nonresponders.

58 tinguish weight and glycemic responders from nonresponders.

59 ation of Klebsiella pneumoniae compared with nonresponders.

60 rate (HR) of overall death in responders and nonresponders.

61 sor distinguished subsequent responders from nonresponders.

62 d a higher amplitude and mesor compared with nonresponders.

63 output and the proportion of responders and nonresponders.

64 duction >90%) and five partial responders or nonresponders.

65 m high-density RT-PCR between responders and nonresponders.

66 e blood of clinical responders as opposed to nonresponders.

67 combined response or HBsAg loss) compared to nonresponders.

68 36/44); 18% (8/44) were considered treatment nonresponders.

69 as moderately but significantly increased in nonresponders.

70 py showed significantly better survival than nonresponders.

71 ne was more pronounced in responders than in nonresponders.

72 was unchanged after fluid challenge in both nonresponders (0.72 [0.67-0.75] before and 0.71 [0.67-0.

73 t 6 months, while a decrease was observed in nonresponders (+0.2+/-0.4 L and -0.1+/-0.4 L, respective

74 gray matter partial volume for responders vs nonresponders, 0.47 [0.03] vs 0.66 [0.03]; corresponding

75 ed the hepatitis E virus (HEV) except for 2 (nonresponders); 1 patient died.

76 esponders (median 3.97 kU/l, n = 19) than in nonresponders (10.9 kU/l, n = 18, P = 0.010).

77 ity-time integral more in responders than in nonresponders (12% +/- 5% vs 5% +/- 2%, respectively; p

78 ers" (24-month C-peptide >/= baseline), and "nonresponders" (12-month C-peptide < baseline) were eval

79 72.2 +/- 107.3 mum) was greater than that of nonresponders (209.6 +/- 85.8 mum; P = .039).

80 Compared to histologic nonresponders (25/35), histologic responders (10/35) had

81 mized crossover phase (9 responders [56%], 7 nonresponders [44%]).

82 a survival difference between responders and nonresponders (45.0 months vs 10.0 months, 84.3 months v

83 response differential was observed among ECT nonresponders (59.6% compared with 34.1%).

84 RSDc was higher in responders compared with nonresponders (74+/-39% versus 29+/-15%; P<0.001) and re

85 provement in LVEF by >/=5 U responder versus nonresponder [95% confidence intervals] for all-cause mo

86 When compared with early metabolic nonresponders, a DeltaTLG decrease of 38% or more was as

87 patients responding at 6 months and 58% for nonresponders according to NIH response, suggesting that

88 ession-free survival (PFS) in responders and nonresponders according to VTB criteria was compared by

89 In nonresponders across 5 datasets GMV was significantly lo

90 n 15 of 20 responders compared with 10 of 22 nonresponders after 4 cycles.

91 on the Lille model, which defines treatment nonresponders after 7 days of initiation of treatment.

92 e this activation pattern partly resolved in nonresponders after CBT, successful treatment was charac

93 identified similar numbers of responders and nonresponders after ketamine or imipramine treatment.

94 Nonresponders also had lower w4IgE levels and lower rati

95 Responders and nonresponders also showed opposite patterns of hemispher

96 can be used to differentiate responders from nonresponders among patients with clinically active Croh

97 can be used to differentiate responders from nonresponders among patients with clinically active Croh

98 thod correctly classified 7 responders and 3 nonresponders among the 10 treated animals); (2) recogni

99 ding to CT RECIST at 12 weeks, there were 21 nonresponders and 11 responders.

100 Eight patients, including 6 nonresponders and 2 responders, developed new cytogeneti

101 There were 24 pathologic nonresponders and 27 responders.

102 ders (P < 0.01); 58.3% of serum samples from nonresponders and 7.6% of serum samples from responders

103 re contrasted between placebo responders and nonresponders and compared to healthy controls (n = 20).

104 EMMA correctly classified 96% as responders/nonresponders and correctly classified 79% according to

105 Twelve of 22 were nonresponders and exhibited earlier onset of jaundice (<

106 during an LCD enables the identification of nonresponders and may help clinicians manage metabolic o

107 omparing demographic characteristics between nonresponders and responders.

108 from SMO in four of four tissue samples from nonresponders and upstream of SMO in two of four patient

109 ealthy versus pathological, responder versus nonresponder) and for generation of an individual metabo

110 n 102/120 (85%) patients, with 7 relapses, 1 nonresponder, and 10 deaths (liver-related complications

111 g]-positive and 4 HBeAg-negative), 7 matched nonresponders, and 7 healthy controls.

112 tion index were assessed between responders, nonresponders, and healthy controls.

113 The muscle transcriptomes of the nonresponders are further characterized by the activatio

114 dian Treg cell counts 3 months post-ECP than nonresponders, as did steroid responders at 56 weeks who

115 Responders were defined as positives and nonresponders, as negatives.

116 1 second (FEV1) of omalizumab responders and nonresponders at 6 months.

117 Patients that were clinical nonresponders at week 2 had significantly higher fecal c

118 ers at 1 mo had better overall survival than nonresponders, at 8.5 mo versus 4.8 mo (P = 0.018); AFP

119 allow repeat vaccination series for initial nonresponders before transplantation.

120 CXCL4 and CXCL7, which were overexpressed in nonresponders, blocked DAC effects in isolated normal CD

121 ht SFG, where GMV was significantly lower in nonresponders but higher in responders.

122 nge on central venous pressure is greater in nonresponders, but not the change observed 10 minutes af

123 s used to classify patients as responders or nonresponders by following standard guidelines for the u

124 levels were compared between responders and nonresponders by mRECIST criteria by using unpaired Wilc

125 Responders did not differ from nonresponders by sex or previously collected medical his

126 AdV-related mortality was 100% in nonresponders compared with 9.5% in responders (>/=1 log

127 D4(+) T cells from HCV-infected, HBV vaccine nonresponders compared with HBV vaccine responders.

128 arison of overall survival of responders and nonresponders demonstrated P values of .4133, .0112, .00

129 loperidol (control group) were compared with nonresponders (dexmedetomidine group).

130 Nonresponders did not consistently show these connection

131 Responders and nonresponders did not differ in the percent change of ri

132 who did not return the consent form and 163 nonresponders did not participate.

133 e VTB separated patients into responders and nonresponders, each with significantly different PFS, an

134 In contrast, CD4 T cells of nonresponders exhibited increased expression of IL2 and

135 008 vs 0.003) and Dutch infants and Ghanaian nonresponders (FDR, 0.002 vs 0.009).

136 ons between both Ghanaian RVV responders and nonresponders (FDR, 0.008 vs 0.003) and Dutch infants an

137 icantly different between RVV responders and nonresponders (FDR, 0.12), and Ghanaian responders were

138 mentation with A. muciniphila after FMT with nonresponder feces restored the efficacy of PD-1 blockad

139 Mean scar volume was higher among CRT nonresponders for both the LV (23+/-23% versus 8+/-14% [

140 Nonresponders from the clozapine group received an 8-wee

141 g) after CPAP, which were not present in the nonresponder group (</=4.5 mm Hg) (p < 0.01).

142 horoidal thickness (243 +/- 15 mum) than the nonresponder group (21 eyes, 198 +/- 13 mum, P = .03).

143 horoidal thickness (239 +/- 12 mum) than the nonresponder group (25 eyes, 211 +/- 16 mum, P = .08).

144 e responder group (p = 0.016) but not in the nonresponder group.

145 On D1, ketamine nonresponders had a lower mesor and a blunted 24-hour am

146 Nonresponders had evidence of steroid resistance; histol

147 Responders and nonresponders had markedly different changes in serum cy

148 (HR = 0.59; 95% CI = 0.32-1.08) and chronic nonresponders (HR = 0.48; 95% CI = 0.23-0.99).

149 RL, we classified patients as responders and nonresponders in 60 and 40 cases versus 63 and 37 cases,

150 fied using PSF and PSFEARL as responders and nonresponders in 69 and 26 cases versus 72 and 23 cases,

151 VR on long-term mortality risk compared with nonresponders in a range of populations.

152 Treatment nonresponders in both cohorts had a statistically signif

153 disease progression, the overall survival of nonresponders in both cohorts was not significantly diff

154 Participants identified as nonresponders in insulin sensitivity (based on the Matsu

155 IL-2 production in HCV-infected, HBV vaccine nonresponders in response to TCR stimulation.

156 tween 6-week old, matched RVV responders and nonresponders in rural Ghana.

157 gy provides relative benefits for sertraline nonresponders in social anxiety disorder.

158 Nonresponders in the induction study received 100 mg gol

159 virological nonresponders were also clinical nonresponders, in spite of a transient improvement in so

160 : mean, -41.0%; P < .001 for both), while in nonresponders it was increased (optical imaging: mean, 1

161 We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T ly

162 Nonresponders largely showed lesser/nonsignificant reduc

163 ferogenic TLR9 agonist, SD-101, in anti-PD-1 nonresponders led to a complete, durable rejection of es

164 Most subjects from TIV nonresponder, low responder, and high responder groups h

165 eceived at least one dose of sertraline; 181 nonresponders (LSAS score >50) at week 10 were randomly

166 ed as KIT responders (>/=25%, n = 17) or KIT nonresponders (<25%, n = 11).

167 for responders than in partial responders or nonresponders (mean +/- standard deviation, 3.23 dB +/-

168 al lesion and the caudate (for responders vs nonresponders, mean [SD] group laterality for individual

169 growth in vitro and a drug responder versus nonresponder molecular signature was defined on the basi

170 eated patients were limited by the number of nonresponders (n = 1).

171 eeks of sham followed by open-label rTMS for nonresponders (n = 12).

172 Results VTB criteria nonresponders (n = 120) according to the initial postthe

173 Results Responders (n = 31) and nonresponders (n = 19) differed (P < .05) in the percent

174 significant difference in PFS between RECIST nonresponders (n = 255) and responders (n = 20; HR = 1.5

175 each class, we designated them as follows: 'Nonresponders' (n = 905, 55%); 'IL-10 responders' (n = 4

176 al and overall survival among responders and nonresponders no matter which reconstruction was used fo

177 response in all domains), 8 (15%) of 54 were nonresponders (no response in any domain), and 39 (72%)

178 ncer patients, partial responders (PR = 18), nonresponders (NR = 13), and complete responders (CR = 1

179 nts were categorized into responders (R) and nonresponders (NR) depending on whether they returned to

180 achieved pCR in 35.7% compared with 19.8% in nonresponders (odds ratio, 2.2; 95% CI, 1.24 to 4.19).

181 ernative therapies for those predicted to be nonresponders or who are at increased risk for adverse s

182 not differ significantly between responders, nonresponders, or controls.

183 s was more significant in responders than in nonresponders (P < .001).

184 VGPR/CR, 64 months for PR, and 28 months for nonresponders (P < .001).

185 re significantly lower in responders than in nonresponders (P < .001): clinical response, 156 vs 725

186 y higher in infliximab-treated responders vs nonresponders (P < .05), and infliximab-treated responde

187 or cells from subsequent IM responders vs IM nonresponders (P < .05).

188 enomedullin level significantly increased in nonresponders (p < 0.0001).

189 rum levels were higher in responders than in nonresponders (P < 0.001).

190 in responders' cells compared with those of nonresponders (P = .0011).

191 patients and decreased in all (five of five) nonresponders (P = .002).

192 ders were more similar to Dutch infants than nonresponders (P = .002).

193 ores were higher in responders compared with nonresponders (P = .02) and remained significant when BR

194 S >/= 18.8 degrees as opposed to only 16% of nonresponders (P = 0.001).

195 erall survival of 13.3 mo, versus 6.9 mo for nonresponders (P = 0.021).

196 responders vs mean decrease of 2.2 points in nonresponders, P = .04).

197 y outcome vs an increase of 0.10 +/- 0.98 in nonresponders; P < .001).

198 aian infants, including 39 RVV responder and nonresponder pairs.

199 upon CD40L/IFN-gamma activation in clinical nonresponder patient DCs, and gp100-specific T cells fro

200 Moreover, in the RTX- nonresponder patient group, the CD8(+) T-cell repertoire

201 esponse index to differentiate responder and nonresponder patients and had substantial agreement with

202 difference between omalizumab responder and nonresponder patients remain inconclusive.

203 ndex for the discrimination of responder and nonresponder patients was evaluated by receiver operatin

204 46 and 18 clinically diagnosed responder and nonresponder patients, the quantitative response index a

205 cies of nonclassical monocytes compared with nonresponder patients.

206 oduction defect in DCs derived from clinical nonresponder patients.

207 old correctly identified 42 responder and 17 nonresponder patients.

208 At day 10, compared with nonresponders, patients with a pain response had a great

209 response had better PFS and OS compared with nonresponders (PFS: HR, 0.40; 95% CI, 0.38 to 0.42; OS:

210 nders did not have a lower tumor burden than nonresponders pretreatment, suggesting that the T cells

211 platelet reactivity and the total number of nonresponders (PRU >/=230) with clopidogrel did not chan

212 2) = -0.02, p = 0.61), or in fluid challenge nonresponders (r(2) = 0.08, p = 0.27).

213 Chronic nonresponders received nadolol+prazosin and had a third

214 rouracil/vincristine/doxorubicin (C5VD), and nonresponders received six cycles of C5VD alone.

215 erences were observed between responders and nonresponders regarding levels of IgE sensitization to A

216 GED was effective in almost a third of FFGED nonresponders, resulting in a combined efficacy of 72% o

217 owed similar BW loss compared with sham, but nonresponders retained impaired glucose tolerance.

218 ells of a subset of responders compared with nonresponders revealed enrichment of T-cell exhaustion-s

219 s in immune responses between responders and nonresponders seemed to correlate with the immune status

220 reported that antidepressant responders and nonresponders show different alterations in brain grey m

221 Compared with responders, nonresponders showed markedly higher baseline anhedonia

222 Interestingly, nonresponders showed prominent hypogyria at bilateral in

223 eline functional magnetic resonance imaging, nonresponders showed significantly lower connectivity th

224 After RYGB, responders and nonresponders showed similar BW loss compared with sham,

225 icrobiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversi

226 1 (all patients) and 2 (rerandomized placebo nonresponders) showed significantly reduced NPI Agitatio

227 Responders and nonresponders spent 54% and 97% of their total disease d

228 artial response, n = 5) and 11 patients were nonresponders (stable disease, n = 9; progressive diseas

229 during the interconversion of responder and nonresponder state.

230 urvival categories based on responder versus nonresponder status according to MR imaging ADC and VE c

231 heart failure patients in CRT responder and nonresponder status using clinical and genetic parameter

232 ification of CRT patients into responder and nonresponder status, including combinations of the ident

233 chronic hepatitis B with HBsAg clearance and nonresponders suggest that NK cells play a role in the c

234 ulate metabolism was significantly higher in nonresponders than remitters.

235 In nonresponders, the percent change in IL-6 on the day aft

236 In responders and nonresponders, the respective progression-free survival

237 n tDV, while no decrease was observed in all nonresponders; this difference between responders and no

238 olymerase was detected in the HEV RNA of the nonresponders; this mutation did not provide the virus w

239 edictable differences between samples (e.g., nonresponder to treatment).

240 protein levels were significantly higher in nonresponders to antihistamines as compared to responder

241 immunodeficiency virus (HIV)-positive immune nonresponders to antiretroviral therapy (ART).

242 In immune nonresponders to ART, rifaximin minimally affected micro

243 her PRM(-) and a lack of change in PRM(+) in nonresponders to bevacizumab therapy implies that tumors

244 complete or partial responders) relative to nonresponders to biological-targeted treatments.

245 ior therapy, 11 remitters to escitalopram, 9 nonresponders to cognitive behavior therapy, and 6 nonre

246 a PET tracer to distinguish responders from nonresponders to epidermal growth factor receptor-target

247 ponders to cognitive behavior therapy, and 6 nonresponders to escitalopram.

248 ity-time integral more in responders than in nonresponders to fluid administration (11% +/- 5% vs 3%

249 Nonresponders to omalizumab had significantly lower bIgE

250 or 3 HCV, those with cirrhosis, and/or prior nonresponders to pegylated interferon-based regimens.

251 In an open-label extension, nonresponders to placebo received thalidomide for an add

252 e 1b (GT1b) infection with cirrhosis and for nonresponders to prior pegylated interferon and ribaviri

253 isional surgery for OAG or OHT; and no known nonresponders to prostaglandins.

254 hus have a use in identifying responders and nonresponders to PS therapy.

255 essed the response of HIV-1-infected initial nonresponders to revaccination with a standard HBV vacci

256 s, 12 spleens from ITP patients who had been nonresponders to RTX therapy were compared with 11 splee

257 P improves differentiation of responders and nonresponders to the drug.

258 remission on the FFGED and 6 of the 19 (31%) nonresponders to the FFGED were successfully rescued wit

259 Nonresponders to tick-borne encephalitis (TBE) or hepati

260 exist to distinguish future responders from nonresponders to treatment during the first episode of p

261 However, in comparison with nonresponders, tumor-specific cells from responder mice

262 G (responders) remained on the drugs whereas nonresponders underwent only variceal band ligation.

263 Subpopulations of Ex4 extreme responders and nonresponders underwent RYGB surgery.

264 baseline that distinguished responders from nonresponders using next-generation sequencing.

265 disorder, both antidepressant responders and nonresponders, using the anisotropic effect size version

266 In volume-nonresponders, volume expansion did not significantly ch

267 ponses (median concentration, 5.01 mug/mL in nonresponders vs 0.54 mug/mL in responders; P = .0047).

268 esponders had distinct features from that of nonresponders, warranting further study.

269 ve of central venous pressure was smaller in nonresponders was 0.12.

270 ders; this difference between responders and nonresponders was significant (P = .001).

271 th established RA, serum reactivity in DMARD nonresponders was significantly higher than that in DMAR

272 fter completion of NAC (partial/complete vs. nonresponders) was poorly correlated to the risk of rela

273 distinguish between treatment responders and nonresponders, we herein submit a novel animal experimen

274 ations did not differentiate responders from nonresponders, we identified 167 differentially methylat

275 as high for (18)F-FDG PET/CT responders than nonresponders (week 2: 42% vs. 21%, P = 0.12; week 6: 44

276 onsecutively selected, and CRT responder and nonresponder were matched for their baseline parameters

277 All virological nonresponders were also clinical nonresponders, in spite

278 rmity for pathologic complete responders and nonresponders were compared by using the Mann-Whitney U

279 A subgroup of vaccine nonresponders were compared to responders and found to h

280 vity index score compared with baseline) and nonresponders were compared with Mann-Whitney test.

281 Nonresponders were contacted by phone or e-mail for addi

282 nges in gene expression in responders versus nonresponders were decreases in NPPA and NPPB and increa

283 an effects between rapid (D1) responders and nonresponders were found at baseline, D1, and D3.

284 Nonresponders were gradually offered a 4-food-group elim

285 Stable populations of responders and nonresponders were identified based on Ex4-induced BW lo

286 Nonresponders were offered a rescue SFGED.

287 All 6 nonresponders were re-treated; 4 had resolution of diarr

288 If all nonresponders were without complaints, the prevalence wo

289 itis (74% men, 57% genotype 1a, 63% previous nonresponders) were included.

290 KD patients (126 IVIG responders and 24 IVIG nonresponders) were recruited for this study.

291 ifference in survival between responders and nonresponders, whereas vRECIST (hazard ratio, 0.6; 95% C

292 (mean, 122 days; 15 survivors) compared with nonresponders who all died shortly after ACT (mean, 24 d

293 Nonresponders who received placebo on day 1 were randoml

294 roportion of the 32 responders (18%) than in nonresponders who received variceal band ligation (31%)

295 s of dementia were similar in responders and nonresponders who refused (35% and 38%), and among respo

296 maging distinguished treated responders from nonresponders with excellent predictive ability.

297 sponders were treated with nadolol and acute nonresponders with nadolol+nitrates.

298 ter IC1 were compared between responders and nonresponders with the Mann-Whitney U test.

299 populations in 29 patients (22 responders, 7 nonresponders) with relapsed chronic myelogenous leukemi

300 t sera obtained from clinical responders and nonresponders within a cohort of 82 patients with grass